Paper40928680
Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.
Foudah AI and 7 others. Mol Divers, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma. Papers, record 40928680. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40928680
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Protein Kinase Inhibitors | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Cyclin-Dependent Kinases | Major topic |
| Humans | |
| Molecular Dynamics Simulation | |
| Molecular Docking Simulation | |
| Quantum Theory |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PSAU/2024/03/31934 | Prince Sattam bin Abdulaziz University, Saudi Arabia | PubMed |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37300379 | Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making. | Hepatology | 2025 | https://conductscience.org/library/papers/37300379 | PubMed |
| 2 | 29066575 | CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC. | Gut | 2018 | https://conductscience.org/library/papers/29066575 | PubMed |
| 3 | 26583988 | PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. | J Chem Theory Comput | 2013 | https://conductscience.org/library/papers/26583988 | PubMed |
| 4 | 36472800 | Integrated genomic analyses of hepatocellular carcinoma. | Hepatol Int | 2023 | https://conductscience.org/library/papers/36472800 | PubMed |
| 5 | 39858059 | Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39858059 | PubMed |
| 6 | 36564979 | Implementation of real-time TDDFT for periodic systems in the open-source PySCF software package. | J Comput Chem | 2023 | https://conductscience.org/library/papers/36564979 | PubMed |
| 7 | 30455585 | Update in global trends and aetiology of hepatocellular carcinoma. | Contemp Oncol (Pozn) | 2018 | https://conductscience.org/library/papers/30455585 | PubMed |
| 8 | 31056726 | Epigenetics of hepatocellular carcinoma. | Clin Transl Med | 2019 | https://conductscience.org/library/papers/31056726 | PubMed |
| 9 | 32888462 | Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32888462 | PubMed |
| 10 | 34114752 | Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. | Cancer Rep (Hoboken) | 2022 | https://conductscience.org/library/papers/34114752 | PubMed |
| 11 | 38728273 | Novel barostat implementation for molecular dynamics. | J Chem Phys | 2024 | https://conductscience.org/library/papers/38728273 | PubMed |
| 12 | 34245122 | Global mapping of cancers: The Cancer Genome Atlas and beyond. | Mol Oncol | 2021 | https://conductscience.org/library/papers/34245122 | PubMed |
| 13 | 32399427 | A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. | Liver Cancer | 2020 | https://conductscience.org/library/papers/32399427 | PubMed |
| 14 | 32734663 | The Bio3D packages for structural bioinformatics. | Protein Sci | 2021 | https://conductscience.org/library/papers/32734663 | PubMed |
| 15 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 16 | 38058419 | Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis. | Liver Cancer | 2023 | https://conductscience.org/library/papers/38058419 | PubMed |
| 17 | 39558165 | PubChem 2025 update. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/39558165 | PubMed |
| 18 | 15264254 | UCSF Chimera--a visualization system for exploratory research and analysis. | J Comput Chem | 2004 | https://conductscience.org/library/papers/15264254 | PubMed |
| 19 | 38523466 | Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. | J Liver Cancer | 2024 | https://conductscience.org/library/papers/38523466 | PubMed |
| 20 | 38201624 | Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38201624 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDK20 | 23552 | PubTator's text mining | https://conductscience.org/library/genes/23552 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40928680
GET https://conductscience.org/api/papers/v1/40928680/references?page=2